Page 3 - Safety Study News Today

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses ...

23.02.2024 - Positive results from the MANDARA Phase III trial for FASENRA (benralizumab) in patients with EGPA were published in the New England Journal of Medicine today,1 as the first head-to-head trial of biologics in patients with EGPA,2 and the first to ...

Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A 1 Anti-TL1A was shown to be safe and well-tolerated, with a low incidence of antidrug...

/PRNewswire/ -- SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica that develops innovative technologies and science-based treatments...

SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica that develops innovative technologies and science-based treatments to address the global myopia epidemic, today announced that the U.S. Food and Drug Administration (FDA) has...

Researchers conducted a case-control study of biometric and pharmaceutical data from 34 patients with delusions of parasitosis, which they compared to an age-matched control group of 53 women.

This is the first approved treatment for wounds associated with JEB and the second for patients with DEB, following the approval of a topical gene therapy in May 2023.

The best collagen supplements can help keep your skin looking young and healthy. Find out the 5 best collagen supplements in 2023.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of FASENRA to three injections per month of mepolizumab ...